# Aligos Therapeutics

Type: Company (ALGS)

Source: GetYourBrief — https://getyourbrief.com/entity/aligos-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/aligos-therapeutics

## Recent coverage (2 stories, network-wide)

### Atlanticus EPS Beats by $0.08 as Insiders Sell $7.9M in Stock
2026-08-09 17:05:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics. Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment. With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
Full story: https://getfinancebrief.com/story/atlanticus-earnings-insider-selling-7-9m

### Aligos Therapeutics Beats Q2 Consensus by $0.95 EPS, Signaling Clinical Momentum
2026-08-09 17:05:04 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Aligos Therapeutics (ALGS) handily beat Q2 consensus earnings per share by $0.95, a significant outperformance for the clinical-stage biotech. This beat may reflect operational efficiencies, milestone payments, or clinical progress in its liver disease pipeline. Investors in the biotech space should watch for full financial disclosures to gauge the sustainability of this positive surprise.
Full story: https://getbiobrief.com/story/aligos-earnings-beat-0-95-eps

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.